NCT04620759View on ClinicalTrials.gov

Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder

PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

April 14, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Major Depressive DisorderAlcohol Use Disorder
Interventions
DRUG

Psilocybin

The psilocybin used in this study is synthetically manufactured and formulated under current good manufacturing practices (cGMP). The active drug is encapsulated using a size 0 blue gelatin capsule and contains 25 mg of psilocybin.

DRUG

Placebo

The placebo used in this study is microcrystalline cellulose, an inert substance, encapsulated using a size 0 blue gelatin capsule.

Trial Locations (1)

21224

RECRUITING

Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore

All Listed Sponsors
collaborator

Usona Institute

OTHER

lead

Johns Hopkins University

OTHER